Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15819837 | 0.89 | GPR119 (0.69) | GPR119KMT2ANR3C1 | |
| SCHEMBL21060691 | 0.88 | GPR119 (0.68) | GPR119NR3C1 | |
| SCHEMBL12459057 | 0.88 | GPR119 (0.68) | GPR119MAPTNR3C1 | |
| SCHEMBL10060450 | 0.88 | GPR119 (0.68) | GPR119NR3C1 | |
| SCHEMBL29507014 | 0.88 | GPR119 (0.68) | GPR119NR3C1 | |
| SCHEMBL17109248 | 0.87 | GPR119 (0.67) | GPR119KMT2ANR3C1 | |
| SCHEMBL13537501 | 0.87 | GPR119 (0.67) | GPR119MAPTNR3C1 | |
| SCHEMBL15701836 | 0.86 | GPR119 (0.66) | GPR119TP53NR3C1 | |
| SCHEMBL17092683 | 0.85 | GPR119 (0.61) | GPR119KMT2ATP53MAPTLMNA | |
| SCHEMBL3354544 | 0.84 | GPR119 (0.66) | GPR119MAPTLMNANR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160355511-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2016-12-08 | — | — | US | disclosed |
| US-20160355511-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2016-12-08 | — | — | US | disclosed |
| US-20160355511-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2016-12-08 | — | — | US | disclosed |
| US-9309221-B2 | 1-substituted indazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-04-12 | — | — | US | disclosed |
| US-9309221-B2 | 1-substituted indazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-04-12 | — | — | US | disclosed |
| US-9309221-B2 | 1-substituted indazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-04-12 | — | — | US | disclosed |
| US-9051295-B2 | 1-substituted indazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9051295-B2 | 1-substituted indazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9051295-B2 | 1-substituted indazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-06-09 | — | — | US | disclosed |
| EP-2837623-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2015-02-18 | — | — | EP | disclosed |
| US-8765786-B2 | 1-substituted indazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8765786-B2 | 1-substituted indazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8765786-B2 | 1-substituted indazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20140121244-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20140121244-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20140121244-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20140121243-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20140121243-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20140121243-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2014-05-01 | — | — | US | disclosed |
| WO-2013154109-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2013-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121244-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | CHRNA3, CHRNB3, CHRNA7 | GPR119 39/4885KMT2A 1897/4885TP53 4809/4885 |
| US-20160355511-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | CHRNA3, CHRNB3, CHRNA7 | GPR119 39/4885KMT2A 1897/4885TP53 4809/4885 |
| US-20140121243-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | CHRNA3, CHRNB3, CHRNA7 | GPR119 39/4885KMT2A 1897/4885TP53 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.